Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 3, 2007, Pages 361-367

  Reni, M ^a   Cereda, S ^a   Bonetto, E ^a   Vigano M G ^a   Passoni, P ^a   Zerbi, A ^a   Balzano, G ^a   Nicoletti, R ^a   Staudacher, C ^a   Di Carlo, V ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Dose intense PEFG; Pancreatic cancer; PEFG regimen

Indexed keywords

CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; RALTITREXED; TEMSIROLIMUS;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE COUNT; HAND FOOT SYNDROME; HEALTH CARE ACCESS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OUTPATIENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PATIENT COMPLIANCE; PERFORMANCE; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 33845909834     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0277-7     Document Type: Article

References (34)

1. Moore MJ, Goldstein D, Hamm J et al (2005) Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trial Group (NCIC-CTG). In: Proceedings of the 2005 Gastrointestinal Cancers Symposium, Hollywood, FL, USA, 3: abstr 77, 27-29 Jan 2005
2. Cunningham D, Chau I, Stocken D et al (2005) Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 3:12 (abstr PS 11)
3. Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol 6:369-376
4. Reni M, Passoni P, Panucci MG et al (2001) Definitive results of a phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in stage IV pancreatic adenocarcinoma. J Clin Oncol 19:2679-2686
5. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
6. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275
7. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A et al (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296-3302
8. Rocha Lima CMS, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783
9. Bramhall SR, Schultz J, Nemunaitis J, Brown PD, Baillet M, Buckels JAC (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167
10. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA, for the Marimastat Pancreatic Cancer Study Group (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3477-3455
11. Heinemann V, Quietzsch D, Gieseler F, Gonnermann N, Schonekas H, Rost A, et al. (2003) A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 22 (abstr 1003)
12. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438
13. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A (2005) Gemcitabine in combination with Oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516
14. O'Reilly EM, Abou-Alfa GK, Letorneau R, Harker WG, Modiano M, Hurwitz H et al (2004) A randomized phase III trial of DX-8951f (exatecan mesylate) and gemcitabine vs. gemcitabine alone in advanced pancreatic cancer. Proc Am Soc Clin Oncol 23 (abstr 4006)
15. Oettle H, Richards DA, Ramanathan R, Van Laethem JL, Peeters M, Fuchs M et al (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639-1645
16. Cheverton P, Friess H, Andras C et al (2004) Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 23:314s (abstr 4005)
17. Dell'Oro S, Reni M, Bonetto E et al (2004) Intensified PEFG regimen in stage III-IV pancreatic adenocarcinoma. Ann Oncol 15:242 (abstr 919)
18. Therasse P, Arbuck SG, Eisenhaur EA, Wanders J, Kaplan RS, Rubinstein L et al (2004) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
19. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147-159
20. Reni M, Passoni P, Bonetto E et al (2005) Final results of a prospective trial of a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology 68:239-245
21. Topham C, Glees J, Coombs R et al (1993) Comparison of single agent epirubicin and 5-FU/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. Oncology 50:78-83
22. Wils JA, Bleiberg H, Blijham G et al (1985) Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer 21:191-194
23. Wils JA, Kok T, Wagener DJ et al (1993) Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 29A:203-204
24. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T et al (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20:3130-3136
25. Hidalgo M, Castellano D, Paz-Ares L et al (1999) Phase II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17:585-592
26. Rothman H, Cantrell JE, Lokich J et al (1991) Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic adenocarcinoma: a Mid-Atlantic Oncology Program study. Cancer 68:264-268
27. Nicolson M, Webb A, Cunningham D et al (1995) Cisplatin and protracted venous infusion 5-fluorouracil (CF) - good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol 6:801-804
28. Rougier P, Zarba JJ, Ducreux M et al (1993) Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 4:333-336
29. Scheitauer W, Kornek GV, Raderer M et al (1999) Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 80:1797-1802
30. Heinemann V, Wilke H, Mergenthaler H-G et al (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399-1403
31. Ducreux M, Rougier P, Pignon JP, Douillard JY, Seitz JF, Bugat R et al (2002) A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13:1185-1191
32. Evans TRJ, Lofts FJ, Mensi JL et al (1996) A phase II study of continuous infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 73:1260-1264
33. El-Rayes BF, Zalupski MM, Shields AF et al (2003) Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 21:2920-2925
34. Reni M, Bonetto E, Cordio S, Passoni P, Milandri C, Cereda S, et al. (2006) Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology (in press)